Rydex Biotechnology Fund Class C (RYCFX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks to provide capital appreciation. Under normal circumstances- the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives- which primarily consist of futures contracts and options on securities- futures contracts- and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.


1 month+1.09% 3 years-1.27%
3 months+5.77% 5 years+15.55%
1 year+23.17% Since inception+8.42%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+15.55%+17.28%
Expense ratio2.36%1.30%
Risk 5 year sharpe ratio0.731.02
Net assets$297.6M$3.1B
Average market cap$13.2B$10.4B
Average P/E29.822.9
Portfolio turnover207%207%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyRydex Funds
Fund manager & tenureMichael Byrum / 19 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00


U.S. stock99.38%
International stock0.00%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ABBV AbbVie7.03%
AMGN Amgen5.55%
GILD Gilead Sciences4.83%
CELG Celgene3.49%
BIIB Biogen3.46%
VRTX Vertex Pharmaceuticals Inc3.34%
ILMN Illumina Inc2.82%
SHPG Shire2.73%
REGN Regeneron Pharmaceuticals2.54%
ALXN Alexion Pharmaceuticals Inc2.51%